Small-sized and lightweight compared to dominant US-made devices. The diameter is reduced by 40%, and the weight is reduced by 50%.
Implantation surgery is less invasive.
Low power consumption of up to 33 hours, with long endurance and a 50% reduction in the weight of peripherals.
Implantation surgery is less invasive.
Low power consumption of up to 33 hours with long endurance and 50% reduction in the weight of peripherals.
Fewer Infections with extra long durability Both percutaneous cable infection and severe infection have been reported as 0 case in clinical trial.
Better hemocompatibility with faster recovery of patients compared to similar LVADs.
Fewer Infections with extra long durability Both percutaneous cable infection and severe infection have been reported as 0 case in clinical trial.
Better hemocompatibility with faster recovery of patients compared to similar LVADs.
A new multi-center study explores the Corheart 6, an implantable left ventricular assist system, and its impact on survival, heart function, and safety over six months. With zero device failures, significant improvements in heart performance, and a 92.3% survival rate, this study reveals promising results for a growing population with limited treatment options.
Request access now to view the full study and explore the data behind this breakthrough.






Sign up below